CClinicalTrials.gg
CompletedNCT06356168Updated Oct 7, 2026

Virtual Reality in End Stage Kidney Disease

An interventional study of Social Virtual Reality and Individual Virtual Reality in End Stage Kidney Disease, sponsored by University of Pennsylvania. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Treatment

Updated Oct 7, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Sex
All
01

Study summary

The goal of this clinical trial to compare the social virtual reality and individual virtual reality in patients with end stage kidney disease who are hemodialysis. The main aim is to determine if there are differences in symptoms between the groups. Participants will use virtual reality glasses for 30-45 minutes during dialysis sessions for 4 weeks.

Read the detailed description

In a single site, 2-arm (Social Virtual Reality group; Individual Virtual Reality Group), parallel, randomized controlled trial we will enroll 60 subjects (n=30 per group) to assess the effects of Social Virtual Reality to Individual Virtual Reality on symptoms in participants with end stage kidney disease who are receiving hemodialysis.

To compare the effects of social virtual reality to individual virtual reality on loneliness To explore the effects of social virtual reality to individual virtual reality on anxiety and depression.

To compare the effects social virtual reality to individual virtual reality on quality of life.

02

Conditions studied

  • End Stage Kidney Disease
03

In context

Kidney Failure, Chronic

2,085 studies on the registry are indexed under Kidney Failure, Chronic; 261 are open to participants now.

This study's enrollment of 54 is close to the median of 55 across 1,557 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,635 studies on the registry; 239 are open to participants now.

Of its 154 completed or terminated interventional studies of FDA-regulated products, 104 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of end stage kidney disease with hemodialysis 3 times per week for at least 1 month

Exclusion criteria

Exclusion Criteria

  • Acutely ill
  • Active nausea
  • Epilepsy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Social Virtual Reality

    Social Virtual Reality will be delivered using virtual reality glasses for 30-45 minutes during dialysis sessions. Groups of 3 participants will watch a movie or program together through the glasses. They will be able to talk and interact during the session.

    Behavioral: Social Virtual Reality

  • Active comparator
    Individual Virtual Reality

    Individual Virtual Reality will be delivered using virtual reality glasses for 30-45 minutes during dialysis sessions. Those randomized to this arm will watch a movie or program alone through the glasses.

    Behavioral: Individual Virtual Reality

Interventions

  • BehavioralSocial Virtual Reality

    Participants interact using virtual reality during dialysis.

  • BehavioralIndividual Virtual Reality

    Participants use virtual reality alone during dialysis.

06

What researchers measure

Primary outcomes

  1. De Jong Gierveld Scale

    Measures how bad or severe a person's loneliness is. Score range from 11-44; higher scores indicate more loneliness.

    Time frame: Baseline and 4 Weeks

07

Study locations

1 site
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Recruiting→Completed
changed Oct 7, 2026
Primary completion
Aug 31, 2026→Aug 15, 2026 (actual)
Oct 7, 2026
Study completion
Dec 31, 2026→Aug 15, 2026 (actual)
Oct 7, 2026
Enrollment
60 (estimated)→54 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Recruiting→Completed
    Primary completion Aug 31, 2026→Aug 15, 2026 (now actual)
    Study completion Dec 31, 2026→Aug 15, 2026 (now actual)
    Enrollment 60 (estimated)→54 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06356168
Lead sponsor
University of Pennsylvania
Responsible party
Sponsor
First posted
Apr 10, 2024
Start date
Mar 30, 2026
Primary completion
Aug 15, 2026
Completion
Aug 15, 2026
Last update
Oct 7, 2026

Study contacts

Lea Ann Matura, PhD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion